Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach.
Christopher ReganLindsey E ScierkaAlan DardikBritt TonnessenCassius Iyad Ochoa ChaarCostin IonescuEdouard AboianJonathan CardellaNaiem NassiriRaul GuzmanRobert AttaranSameer NagpalSamit ShahKim G SmolderenCarlos Mena-HurtadoPublished in: Vascular (2024)
PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- acute coronary syndrome
- prognostic factors
- peritoneal dialysis
- percutaneous coronary intervention
- clinical trial
- physical activity
- patient reported outcomes
- stem cells
- type diabetes
- open label
- coronary artery disease
- antiplatelet therapy
- metabolic syndrome
- adipose tissue
- patient reported
- atrial fibrillation
- cell therapy